Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.36 |
| ▸ | S100A4 | P26447 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9617118 | 0.85 | CA1 (0.51) | KDM4ETDP1L3MBTL1CYP3A4SMN1; SMN2 | |
| SCHEMBL28777971 | 0.81 | GPR35 (0.45) | KDM4ETDP1TSHRSMN1; SMN2CA1 | |
| SCHEMBL3239188 | 0.73 | TSHR (0.46) | KDM4ETDP1POLBCTDSP1L3MBTL1 | |
| SCHEMBL6363208 | 0.72 | GPR35 (0.48) | KDM4ETDP1POLBCTDSP1L3MBTL1 | |
| SCHEMBL31514658 | 0.72 | CA1 (0.46) | KDM4ETDP1CYP3A4CA1CA2 | |
| SCHEMBL5660720 | 0.72 | CYP3A4 (0.41) | KDM4ETDP1POLBCTDSP1L3MBTL1 | |
| SCHEMBL9617124 | 0.71 | SMN1; SMN2 (0.42) | POLBTSHRSMN1; SMN2LMNAGAA | |
| SCHEMBL11441634 | 0.69 | GPR35 (0.48) | KDM4ETDP1TSHRCYP3A4SMN1; SMN2 | |
| SCHEMBL28134615 | 0.69 | GPR35 (0.36) | KDM4ETDP1CYP3A4CA1CA2 | |
| SCHEMBL31221855 | 0.68 | GPR35 (0.47) | KDM4ETDP1TSHRCYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 629 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9182408-B2 | Method of screening by using conformation sensitive peptides | VALNEVA (FR) | 2015-11-10 | — | — | US | claimed |
| EP-1789799-B2 | METHOD OF SCREENING BY USING CONFORMATION SENSITIVE PEPTIDES | VALNEVA (FR) | 2015-03-11 | — | — | EP | claimed |
| EP-1789799-B1 | METHOD OF SCREENING BY USING CONFORMATION SENSITIVE PEPTIDES | VIVALIS (FR) | 2011-11-09 | — | — | EP | claimed |
| US-20080076669-A1 | Method of screening by using conformation sensitive peptides | VALNEVA (FR) | 2008-03-27 | — | — | US | claimed |
| EP-1789799-A2 | METHOD OF SCREENING BY USING CONFORMATION SENSITIVE PEPTIDES | Vivalis (FR) | 2007-05-30 | — | — | EP | claimed |
| WO-2006046134-A2 | METHOD OF SCREENING BY USING CONFORMATION SENSITIVE PEPTIDES | VIVALIS (FR) | 2006-05-04 | — | — | WO | claimed |
| EP-1637885-A1 | Method of screening by using conformation sensitive peptides | Vivalis (FR) | 2006-03-22 | — | — | EP | claimed |
| JP-1228949-A | — | — | None | — | — | JP | disclosed |
| JP-3095141-A | — | — | None | — | — | JP | disclosed |
| US-12383558-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4556010-A2 | JAK INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF A VIRAL DISEASE CAUSED BY A CORONAVIRIDAE | Emory University (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-4032897-B1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | GILEAD PHARMASSET LLC (US) | 2025-01-29 | — | — | EP | disclosed |
| EP-2970357-B1 | AMINO ACID PHOSPHORAMIDATE PRONUCLEOTIDES OF 2'-CYANO, AZIDO AND AMINO NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2025-01-01 | — | — | EP | disclosed |
| US-20030050229-A1 | Methods and compositions for treating hepatitis C virus | IDENIX PHARMACEUTICALS LLC | 2003-03-13 | — | — | US | disclosed |
| WO-2002048165-A2 | ANTIVIRAL AGENTS FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS | PHARMASSET LTD. (BB) | 2002-06-20 | — | — | WO | disclosed |
| WO-2002032920-A2 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | PHARMASSET LIMITED (BB) | 2002-04-25 | — | — | WO | disclosed |
| WO-2001092282-A2 | METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUSES AND PESTIVIRUSES | IDENIX (CAYMAN) LIMITED (KY) | 2001-12-06 | — | — | WO | disclosed |
| WO-2001090121-A2 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | IDENIX (CAYMAN) LIMITED (KY) | 2001-11-29 | — | — | WO | disclosed |
| JP-H0395141-A | NOVEL 3-NITRO-2,4,6-TRIHYDOXYBENZOIC ACID AND DERIVATIVE THEREOF AND PRODUCTION THEREOF | JAPAN TOBACCO INC | 1991-04-19 | — | — | JP | disclosed |
| JP-H01228949-A | 3-NITRO-2,4,6-TRIHYDROXYBENZAMIDE AND PRODUCTION THEREOF | RIKAGAKU KENKYUSHO | 1989-09-12 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050229-A1 | Methods and compositions for treating hepatitis C virus | HAVCR2, HCCS, SLC10A1 | KDM4E 4422/4885TDP1 2361/4885POLB 847/4885 |
| US-12383558-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | JAK1, JAK3, PNP | KDM4E 628/4885TDP1 443/4885POLB 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.